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ABSTRACT 
The aim of this pilot study was to describe indicators present at the end of life in 
persons with chronic kidney disease. Retrospective chart reviews of 10 randomly 
selected patients were conducted to describe demographic, physiological, and 
functional variables. Using a repeated measures ANOVA, The Palliative 
Performance Scale and the Braden Scale both showed significant differences 
during the death admission from previous admissions. These functional 
measures may provide useful insight in identifying the end of life in persons with 
chronic kidney disease. 
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Introduction  
Approximately 336,000 Americans have chronic kidney disease (CKD) requiring 
dialysis, and well over 84,000 dialysis patients died in 2004.1 Patients with end 
stage renal disease (ESRD) must be kept alive with dialytic therapy and 
discontinuation usually results in death within eight days.2 Many of these deaths 
are characterized by a diminished quality of life and medical futility.3 More 
importantly, few ESRD patients receive hospice and palliative care.4 The lack of 
end-of-life care may be related to the small time frame from discontinuation of 
dialysis until death or that the patients and families are not prepared to receive 
palliative care. Another reason these patients may not receive palliative care is 
that the identification of the dying trajectory in ESRD is unclear, thus preventing 
the nurse from initiating effective end-of-life planning. Mobilization of end-of-life 
resources is essential in facilitating a good death, which is often described as a 
spiritually meaningful, peaceful and pain-free end to one’s life.5  
Identifying the end of life, therefore, may facilitate a good death. Literature 
indicates that various functional and physiological indicators have been 
successful in identifying ESRD patients at risk for death. Functional indicators 
provide an assessment of the extent to which a person can perform activities of 
daily living, such as bathing and eating. Physiological indicators provide an 
objective assessment of physical health as determined by clinician assessment 
or other diagnostic test, such as blood pressure or hemoglobin level. None of the 
articles reviewed for this study comprehensively examined functional and 
physiological indicators together as predictors of end of life. 6-12 13-17 Identifying 
these indicators are important in recognizing optimal times to offer palliative care 
to ESRD patients. Therefore, the specific aim of this pilot study was to describe 
functional and physiological indicators present at the end of life in those with 
CKD.  
Methods  
The researchers used a retrospective design to examine indicators of death. A 
retrospective medical chart review was conducted at a large community hospital 
in the southeastern United States and was deemed exempt by the hospital’s 
Institutional Review Board. Ten medical record numbers, representing ten 
individual persons, were randomly selected from a list of all the persons with 
CKD who died at the hospital during 2005 (n= 15). Up to four medical documents 
were collected for each individual: the death record and up to three previous 
admissions’ charts.  
Demographic, physiological, and functional variables were extracted from the 
medical records at each admission and discharge (or death) using a researcher-
designed data collection tool. Functional status was measured using the 
Palliative Performance Scale (PPS).18 The PPS, a modification of the Karnofsky 
Performance Scale (KPS), measures the decline in function seen in terminal 
patients as they approach death. The index ranges from 100% (normal, no 
evidence of disease) to 0% (deceased). The scale progresses in 10% increments 
within these two anchors to describe overall level of function. Persons are 
classified against five categories: ambulation, activity/ evidence of disease, self-
care, intake, and level of consciousness according to descriptors for each 
percentage from 0-100. Because the PPS was designed to predict death, 
evidence of construct validity has been supported by its prognostic capacity.8,17,18 
One study reported good interrater reliability with quadratically weighted kappa = 
0.67 (p < 0.001).8  
Physiological indicators included: mean arterial pressure (MAP), pulse, 
temperature, weight, serum albumin and prealbumin, serum hemoglobin, serum 
glucose and HgbA1c, mean arterial pressure during hemodialysis, dialysis 
transmembrane pressure (TMP), and score on the Braden Scale.19  
The Braden Scale is a norm-referenced scale for measuring pressure ulcer risk. 
It has six distinct subscales that address known pressure ulcer risk factors or 
causes—mobility, activity, sensory perception, moisture, nutrition, and friction/ 
shear. All of the subscales have four statement choices, except for the friction/ 
shear subscale which has three. These statements are assigned a score from 1-
4 (or 1-3 for the friction/ shear subscale) with lower values indicating higher risk 
for pressure ulcer development. The six subscales are summed to determine an 
overall risk assessment. The highest score attainable is 23, which indicates the 
lowest risk for pressure ulcer development; the lowest score attainable is 6, 
which indicates the highest risk. Reliability and validity of the Braden scale has 
remained strong over time.20 Several studies have reported interrater correlation 
coefficients of 0.83 - 0.90.19,21,22 Percent agreement has ranged from 95% to 
100%.23,24 Sensitivities have been reported at 100%,25 while specificities range 
from 64% - 90%.25  
Results  
All data were analyzed using SPSS (version 13), and an alpha level of .05 was 
established for significance. Thirty-four charts representing 10 persons were 
reviewed. Five persons had reached stage 5 CKD requiring hemodialysis. The 
other five persons were in stage 3-4 CKD, and not yet on hemodialysis. No 
statistical differences were found between the patients with ESRD and those in 
stage 3-4 CKD. The majority of the sample was men (51%), White (54%), and 
the mean age was 73 (SD=17). Those on hemodialysis had been receiving this 
treatment for 1.17 (SD= 1.67) years. Sixty-nine percent of the persons had a 
central dialysis catheter, 25% had an arterio-venous fistula, and 6% had a graft.  
The trajectories of physiological and functional indicators are displayed in Table 
1. Prealbumin and HgbA1c were not measured in any of the 34 charts reviewed 
and were dropped from the analyses. Only three variables showed a declining 
trajectory: MAP, Braden Scale, and serum albumin. The PPS noted a declining 
trajectory between the first admission and the final (death) admission. The middle 
two admissions’ PPS scores were not statistically different.  
All variables were compared across the four admission times using a repeated 
measures ANOVA. The MAP, Braden Scale score, and the PPS were all 
significant (see Table 2). Independent t tests for differences between patients 
already on hemodialysis and those not yet on hemodialysis were not significant 
for these three variables.  
In examining the admission just prior to the death admission, the mean number 
of days until death was 68.44 (SD= 68.50). The mean PPS during the admission 
just prior to the death admission was 60.6 (SD= 10.2), and fell to 40.0 (SD= 20) 
on the day of admission for the final hospitalization. The mean Braden Scale 
score during the admission just prior to the death admission was 16.4 (SD= 3.0), 
and fell to 11.2 (SD= 1.8) at death. The MAP during the admission just prior to 
the death admission was 89.9 (SD= 22.3), and fell to 80.8 (SD= 22.9) during the 
final admission.  
Discussion  
While the MAP was significantly different during some of the admissions, there 
was not a difference between the death admission and the admission just prior to 
death. The PPS and the Braden Scale both showed significant differences during 
the death admission from the previous three admissions. Both the PPS and the 
Braden Scale have functional indicators within the scales. Therefore, functional 
measures may provide greater predictive indication of impending death than 
other physiological indicators.  
This study provides early evidence that determination and quantification of 
functional health status for hospitalized persons with CKD may be important to 
document. This documentation will allowing trending changes over time and may 
assist nurses in determining the dying trajectory in patients with CKD. Braden 
Scale scores approaching 11, and PPS scores approaching 40, when factored in 
to the total assessment, may signal that death is near. Palliative care clinicians 
may provide needed support during this critical time. Further research is needed 
to validate the predictive impact of functional status on end of life and the effect 
of early palliative and hospice options on the achievement of good deaths within 
the ESRD population. 
This was a small pilot study to explore some possible indicators present at the 
end of life in persons with CKD. Because the sample was from one hospital, 
external validity is limited. In addition, due to the small sample size, results 
should be interpreted with caution. However, this study may help inform future 
larger studies exploring indicators present at the end of life in persons with CKD. 
The ultimate goal is to assist persons with CKD experience a good death.  
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Table 1 
Mean Values of Physiological and Functional Indicators during Final 
Hospital Admissions 
   Third 
Admission 
Second 
Admission 
Admission 
Prior to Death  
Death Admission  
Prior to Death  Prior to Death  
MAP  105.13  
± 24.45  
94.29  
± 14.96  
89.89  
± 22.28  
80.75  
± 22.92  
Pulse  85.44  
± 18.26  
92.93  
± 20.00  
82.83  
± 22.17  
85.55  
± 20.31  
Temp  98.11  
± 0.83  
97.41  
± 1.07  
97.81  
± 0.70  
97.93  
± 1.08  
Weight  104.93  
± 41.57  
92.98  
± 30.69  
79.04  
± 21.32  
101.93  
± 41.51  
Braden Scale  17.29  
± 2.38  
16.43  
± 1.57  
16.43  
± 3.03  
11.27  
± 1.77  
Albumin  3.09  
± 0.60  
2.87  
± 0.33  
2.71  
± 0.60  
2.66  
± 0.67  
Hemoglobin  11.91  
± 1.28  
11.89  
± 1.10  
11.08  
± 1.94  
12.10  
± 1.56  
Glucose  127.07  
± 25.64  
119.57  
± 29.42  
102.93  
± 48.53  
190.35  
± 217.07  
MAP*  54.63  
± 37.89  
87.04  
± 20.96  
73.38  
± 23.63  
61.90  
± 13.49  
TMP*  42.50  
± 28.72  
78.75  
± 26.58  
50.00  
± 18.26  
81.00  
± 35.78  
PPS  68.57  
± 10.69  
57.86  
± 10.75  
60.63  
± 10.16  
20.00  
± 10.00  
*These measurements taken during hemodialysis 
Table 2 
Significant Results of Physiological and Functional Indicators across 
Admissions Using Repeated Measures ANOVA  
   F statistic  Degrees of 
Freedom  
Significance 
level  
Differences 
Between 
Admissions* #  
Mean Arterial 
Pressure (MAP)  
9.580  3, 21  p< 0.001  Death and 3 
Death and 4 
2 and 4  
Braden Scale  8.263  3, 17  p= 0.001  Death and 2 
Death and 3 
Death and 4  
Palliative 
Performance 
Scale (PPS)  
78.918  3, 18  p< 0.001  Death and 2 
Death and 3 
Death and 4 
3 and 4  
*Death= death admission, 2= admission just prior to death, 3= second admission 
prior to death, 4= third admission prior to death# Post hoc analysis using a 
Bonferroni adjustment was used to determine which admissions were different. 
